Hunger Between Doses: What Is Known, and What Nobody Has Measured

The half-lives are well established. The day-by-day story is not. We searched for research tracking hunger, food noise or energy across the days between weekly doses and found none. Here is what the labels actually say, why the appetite trials cannot answer the question, and how to watch your own week.

Reading your own pattern — not medical advice, and no dosing guidance. For anything about your dose or a missed dose, read your medicine's leaflet and ask your prescriber.

By Matt Cole. Editor: Sezen Soykut.

---

Key takeaways

• Both labels describe reduced appetite. Neither says which day of a dosing week that effect is strongest.
• We ran 18 literature searches and found no study measuring hunger, food noise or energy day by day between doses.
• Exposure and time-to-peak differ measurably between people — a reason not to expect one standard week, not an explanation of yours.
• Calorie intake already runs highest Thursday to Sunday in people not on these medicines, so a weekend spike is not evidence about your dose.

---

What the labels establish

Semaglutide has "a prolonged half-life of around 1 week" [1]. Maximum concentration arrives one to three days after a dose; steady state after four to five weeks of once-weekly dosing [1][2]. Tirzepatide's label gives its own numbers: peak concentration 8 to 72 hours post dose, steady state after four weeks, an elimination half-life of approximately five days [3][4].

The appetite effect is label-level too. Semaglutide "reduces appetite by increasing feelings of fullness and satiety" [5]. Tirzepatide "reduces the intensity of food cravings and preferences for high sugar and high fat foods" [3].

Here is the part nobody quotes. Neither label contains a word about timing within a dosing interval. What the effect does on day three versus day six is not what those documents are for.

The honest version

We looked for research that tracks hunger, food noise or energy day by day across the days between weekly doses, and we did not find any. The medicine's half-life is well established; what happens to appetite on day three versus day six has not, as far as we can find, been measured in a published study. So anything you read that states it as fact — including on this page — is going beyond the evidence.

That is the result of 18 searches across Europe PMC and Crossref on 6 October 2026, in every phrasing we could construct for within-week fluctuation and day-of-week effects. A search result is not proof of non-existence. But it is why the usual explanation — levels fall, so hunger returns — is half a fact welded to a guess.

The trials show why. In the landmark semaglutide appetite study, the last dose was given in the evening and the meal test ran the next morning [6]. The longest study assessed appetite at weeks 0, 20, 40 and 60, and states its own limitation: it "only assessed ad libitum intake at a single laboratory test meal", and laboratory studies "may not capture differences in other food intake patterns that arise in a free-living environment" [7].

Why your week may not look like anyone else's

Two people on the same dose are not getting the same exposure. Tirzepatide's peak arrives anywhere from 8 to 72 hours after a dose — a ninefold spread in timing [3]. For semaglutide 2.4 mg, 90% of patients in the phase 3 trials had average steady-state concentrations between 51 and 110 nmol/L, roughly a twofold range [5].

Those are blood levels, not hunger, and no study connects them to how anyone's appetite moves across a week. What the spread supports is modest and useful: there is no standard week you are failing to have. (Different questions, different timescales: why your medication can feel different after months, and why GLP-1s don't work for 1 in 10 people.)

The confound hiding in your weekend

Among 446 adults with obesity in a 16-week behavioural weight-loss programme — no GLP-1 medication involved — there was "significant variation in self-monitoring adherence and caloric intake across days of the week, ps < .001, with the lowest adherence and greatest intake observed on Thursdays through Sundays" [8].

Unless your injection day moves, your dose week and your calendar week sit on top of each other. If you eat more by Saturday, you have found a pattern already present in people not on the medicine at all. Not a reason to dismiss what you notice — a reason to write the calendar day beside the dose day, so the two can eventually be told apart.

How to watch your own week

Researchers who study one person at a time measure repeatedly rather than once, and treat the person as their own comparison [9]. What they also do, and you cannot, is randomise the order of treatment and control periods [10]. So: a diary, not a trial.

• Note the same two or three things at the same time each day. Hunger, food noise, energy. Three marks beat a paragraph you will stop writing.
• Write down the dose day and the calendar day. Without both, Saturday and day six are the same column.
• Give it a few cycles, not one week. Our suggestion, not a research finding — no source we found specifies how long it takes. One week cannot tell a pattern from a bad Tuesday.
• Take a starting point first. Our food noise assessment is an eight-question self-check — a score to compare against later, not a clinical measure.

Logging in Gila, a notebook or your phone gives you something to bring to an appointment. What the record is for is a better conversation with your prescriber, not a conclusion about your medication. (More on the phrase: what food noise is and how to navigate it.)

---

The Gila pilot is free and currently on iPhone: sign up here. Our weekly newsletter is here.

---

Sources

1. European Medicines Agency, Ozempic (semaglutide) EPAR product information, Annex I SmPC §5.2 Pharmacokinetic properties, pp. 24–25. https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf
2. US FDA, OZEMPIC (semaglutide) injection, prescribing information §12.3, via DailyMed (NIH). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
3. European Medicines Agency, Mounjaro (tirzepatide) EPAR product information, Annex I SmPC §5.1 p. 13 and §5.2 pp. 39–40. https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
4. US FDA, MOUNJARO (tirzepatide) injection, prescribing information §12.3, via DailyMed (NIH). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
5. European Medicines Agency, Wegovy (semaglutide) EPAR product information, Annex I SmPC §5.1 p. 14 and §5.2 p. 33. https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf
6. Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity." Diabetes, Obesity & Metabolism 2017;19(9):1242–1251. https://doi.org/10.1111/dom.12932
7. Tronieri JS, Allison KC, DeRouen K, et al. "Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial." The American Journal of Clinical Nutrition 2026;124(2):101403. https://doi.org/10.1016/j.ajcnut.2026.101403
8. Ross KM, Swanson TN, Arroyo KM, Shetty A, Shankar MN, Krukowski RA. "Within-week and within-year patterns in self-monitoring of dietary intake in adults with obesity participating in a behavioral weight loss program." Health Psychology and Behavioral Medicine 2025;13(1):2485476. https://doi.org/10.1080/21642850.2025.2485476
9. De Carvalho MCL, de Matos Dourado Simões M, Adler UC, Junior ABV, de Sousa CNS, Sanders LLO. "N-of-1 trials in clinical research: Methodological foundations, statistical approaches and implementation challenges." British Journal of Clinical Pharmacology 2026;92(3):809–821. https://doi.org/10.1002/bcp.70382
10. Chatters R, Hawksworth O, Julious S, Cook A. "The development of a set of key points to aid clinicians and researchers in designing and conducting n-of-1 trials." Trials 2024;25:473. https://doi.org/10.1186/s13063-024-08261-z